Bausch Health Companies Inc. SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account
Bausch Health Companies Inc. (BHC) reported SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account of $3.01 billion for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Valuation and Qualifying Accounts
us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts · last filed 2026-07-30
- Bausch Health Companies Inc. sec schedule, 12-09, valuation allowances and reserves, additions, charge to other account for the quarter ending 2026-06-30 was $1.54B, a 16.03% decline year-over-year.
- Bausch Health Companies Inc. sec schedule, 12-09, valuation allowances and reserves, additions, charge to other account for the quarter ending 2026-03-31 was $1.47B, a 13.33% decline year-over-year.
- Bausch Health Companies Inc. sec schedule, 12-09, valuation allowances and reserves, additions, charge to other account for the quarter ending 2025-12-31 was $1.80B, a 0.33% decline year-over-year.
- Bausch Health Companies Inc. sec schedule, 12-09, valuation allowances and reserves, additions, charge to other account for the quarter ending 2025-09-30 was $1.85B, a 12.62% increase year-over-year.
- Bausch Health Companies Inc. sec schedule, 12-09, valuation allowances and reserves, additions, charge to other account for fiscal 2025 was $7.18B, a 5.45% increase from fiscal 2024.
- Bausch Health Companies Inc. sec schedule, 12-09, valuation allowances and reserves, additions, charge to other account for fiscal 2024 was $6.81B, a 12.75% increase from fiscal 2023.
- Bausch Health Companies Inc. sec schedule, 12-09, valuation allowances and reserves, additions, charge to other account for fiscal 2023 was $6.04B, a 8.36% increase from fiscal 2022.
- Bausch Health Companies Inc. sec schedule, 12-09, valuation allowances and reserves, additions, charge to other account for fiscal 2022 was $5.57B, a 2.63% increase from fiscal 2021.
| Period end | SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account 3 month | SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account 6 month | SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account 9 month | SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.54B derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $3.01B 10-Q · filed 2026-07-30 | $4.81B derived: sum of 3 quarters · filed 2026-07-30 | $6.66B derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $1.47B 10-Q · filed 2026-04-30 | $3.27B derived: sum of 2 quarters · filed 2026-04-30 | $5.11B derived: sum of 3 quarters · filed 2026-04-30 | $6.95B derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $1.80B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $3.64B derived: sum of 2 quarters · filed 2026-02-19 | $5.48B derived: sum of 3 quarters · filed 2026-07-30 | $7.18B 10-K · filed 2026-02-19 |
| 2025-09-30 | $1.85B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $3.69B derived: sum of 2 quarters · filed 2026-07-30 | $5.38B 10-Q · filed 2025-10-30 | $7.18B derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $1.84B derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $3.54B 10-Q · filed 2026-07-30 | $5.34B derived: sum of 3 quarters · filed 2026-07-30 | $6.98B derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $1.70B 10-Q · filed 2026-04-30 | $3.50B derived: sum of 2 quarters · filed 2026-04-30 | $5.14B derived: sum of 3 quarters · filed 2026-04-30 | $6.81B derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $1.80B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $3.44B derived: sum of 2 quarters · filed 2026-02-19 | $5.11B derived: sum of 3 quarters · filed 2026-02-19 | $6.81B 10-K · filed 2026-02-19 |
| 2024-09-30 | $1.64B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $3.31B derived: sum of 2 quarters · filed 2025-10-30 | $5.00B 10-Q · filed 2025-10-30 | $6.71B derived: sum of 4 quarters · filed 2025-10-30 |
| 2024-06-30 | $1.67B derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $3.37B 10-Q · filed 2025-07-31 | $5.07B derived: sum of 3 quarters · filed 2025-07-31 | $6.55B derived: sum of 4 quarters · filed 2025-07-31 |
| 2024-03-31 | $1.69B 10-Q · filed 2025-05-01 | $3.40B derived: sum of 2 quarters · filed 2025-05-01 | $4.88B derived: sum of 3 quarters · filed 2025-05-01 | $6.36B derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | $1.70B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $3.19B derived: sum of 2 quarters · filed 2025-02-20 | $4.67B derived: sum of 3 quarters · filed 2025-02-20 | $6.04B 10-K · filed 2025-02-20 |
| 2023-09-30 | $1.48B derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $2.96B derived: sum of 2 quarters · filed 2024-10-31 | $4.33B 10-Q · filed 2024-10-31 | $5.76B derived: sum of 4 quarters · filed 2024-10-31 |
| 2023-06-30 | $1.48B derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $2.85B 10-Q · filed 2024-08-01 | $4.28B derived: sum of 3 quarters · filed 2024-08-01 | $5.71B derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $1.37B 10-Q · filed 2024-05-02 | $2.80B derived: sum of 2 quarters · filed 2024-05-02 | $4.23B derived: sum of 3 quarters · filed 2024-05-02 | $5.69B derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | $1.43B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $2.86B derived: sum of 2 quarters · filed 2024-02-22 | $4.32B derived: sum of 3 quarters · filed 2024-02-22 | $5.57B 10-K · filed 2024-02-22 |
| 2022-09-30 | $1.44B derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $2.89B derived: sum of 2 quarters · filed 2023-11-02 | $4.14B 10-Q · filed 2023-11-02 | $5.51B derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $1.45B derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $2.71B 10-Q · filed 2023-08-03 | $4.08B derived: sum of 3 quarters · filed 2023-08-03 | $5.42B derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $1.26B 10-Q · filed 2023-05-04 | $2.62B derived: sum of 2 quarters · filed 2023-05-04 | $3.97B derived: sum of 3 quarters · filed 2023-05-04 | $5.38B derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $1.37B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $2.71B derived: sum of 2 quarters · filed 2023-02-23 | $4.13B derived: sum of 3 quarters · filed 2023-02-23 | $5.43B 10-K · filed 2023-02-23 |
| 2021-09-30 | $1.35B derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $2.76B derived: sum of 2 quarters · filed 2022-11-03 | $4.06B 10-Q · filed 2022-11-03 | $5.40B derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $1.41B derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $2.71B 10-Q · filed 2022-08-09 | $4.05B derived: sum of 3 quarters · filed 2022-08-09 | $5.37B derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $1.30B 10-Q · filed 2022-05-10 | $2.64B derived: sum of 2 quarters · filed 2022-05-11 | $3.96B derived: sum of 3 quarters · filed 2022-05-11 | $5.00B derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $1.34B derived: 8-K 12 month − 10-Q 9 month · filed 2022-05-11 | $2.66B derived: sum of 2 quarters · filed 2022-05-11 | $3.70B derived: sum of 3 quarters · filed 2022-05-11 | $5.04B 8-K · filed 2022-05-11 |
| 2020-09-30 | $1.32B derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $2.36B derived: sum of 2 quarters · filed 2021-11-02 | $3.70B 10-Q · filed 2021-11-02 | $5.12B derived: sum of 4 quarters · filed 2021-11-02 |
| 2020-06-30 | $1.04B derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $2.38B 10-Q · filed 2021-08-03 | $3.80B derived: sum of 3 quarters · filed 2021-08-03 | $5.05B derived: sum of 4 quarters · filed 2021-08-03 |
| 2020-03-31 | $1.34B 10-Q · filed 2021-05-04 | $2.76B derived: sum of 2 quarters · filed 2021-05-04 | $4.01B derived: sum of 3 quarters · filed 2021-05-04 | $5.36B derived: sum of 4 quarters · filed 2021-05-04 |
| 2019-12-31 | $1.43B derived: 8-K 12 month − 10-Q 9 month · filed 2021-05-04 | $2.67B derived: sum of 2 quarters · filed 2021-05-04 | $4.03B derived: sum of 3 quarters · filed 2021-05-04 | $5.29B 8-K · filed 2021-05-04 |
| 2019-09-30 | $1.25B derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-03 | $2.60B derived: sum of 2 quarters · filed 2020-11-03 | $3.86B 10-Q · filed 2020-11-03 | $5.28B derived: sum of 4 quarters · filed 2020-11-03 |
| 2019-06-30 | $1.35B derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $2.61B 10-Q · filed 2020-08-06 | $4.03B derived: sum of 3 quarters · filed 2020-08-06 | $5.54B derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $1.26B 10-Q · filed 2020-05-07 | $2.68B derived: sum of 2 quarters · filed 2020-05-07 | $4.19B derived: sum of 3 quarters · filed 2020-05-07 | $5.72B derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $1.42B derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-19 | $2.92B derived: sum of 2 quarters · filed 2020-02-19 | $4.46B derived: sum of 3 quarters · filed 2020-02-19 | $5.89B 10-K · filed 2020-02-19 |
| 2018-09-30 | $1.51B derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $3.04B derived: sum of 2 quarters · filed 2019-11-04 | $4.47B 10-Q · filed 2019-11-04 | |
| 2018-06-30 | $1.53B derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $2.96B 10-Q · filed 2019-08-06 | ||
| 2018-03-31 | $1.43B 10-Q · filed 2019-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |